Accessibility Menu
 

Synovics Pharmaceuticals

(OTC) SYVC

Current Price$0.00
Market CapN/A
Since IPO (1995)-100%
5 Year+0%
1 Year+0%
1 Month-99%

Synovics Pharmaceuticals Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$19.09M

Net Income (TTM)

$5.04M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-6.64 (Low)

Price

$0.00

Volume

1,400

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

SYVC News

No articles available.

SYVC: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Synovics Pharmaceuticals

Industry

Pharmaceuticals

Headquarters

Fort Lauderdale, US

SYVC Financials

Key Financial Metrics (TTM)

Gross Margin

35%

Operating Margin

-10%

Net Income Margin

-15%

Return on Equity

0%

Return on Capital

-28%

Return on Assets

-18%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$0.00

Shares Outstanding

29.83M

Volume

1.40K

Short Interest

0.00%

Avg. Volume

30

Financials (TTM)

Gross Profit

$8.97M

Operating Income

$2.48M

EBITDA

$1.87M

Operating Cash Flow

$3.86M

Capital Expenditure

$708.30K

Free Cash Flow

$3.15M

Cash & ST Invst.

$65.99K

Total Debt

$6.55M

Synovics Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2009YOY CHG

Revenue

$1.58M

-79.5%

Gross Profit

$579.76K

-119.3%

Gross Margin

-36.73%

N/A

Market Cap

$0.00

N/A

Market Cap/Employee

N/A

N/A

Employees

155

N/A

Net Income

$2.02M

-512.7%

EBITDA

$1.64M

-173.5%

Quarterly Fundamentals

Name
Q3 2009YOY CHG

Net Cash

$4.41M

+46.9%

Accounts Receivable

$1.54M

-58.3%

Inventory

$2.32M

+5.5%

Long Term Debt

$1.99M

-56.8%

Short Term Debt

$2.55M

-38.2%

Return on Assets

-17.93%

N/A

Return on Invested Capital

-28.08%

N/A

Free Cash Flow

$17.62K

-99.2%

Operating Cash Flow

$60.70K

-97.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CMRAComera Life Sciences Holdings, Inc.
$0.00+0.00%
SNNAQSienna Biopharmaceuticals, Inc.
$0.00+0.00%
GBIMGlobeImmune, Inc.
$0.00+0.00%
RBSHRebus Holdings, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$43.87-0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%
INFYInfosys
$13.12+0.01%

Questions About SYVC

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.